NanoMedicines Innovation Network (NMIN)

1. NanoMedicines Innovation Network (NMIN) $18,532,000 5 years (2019-2024) funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program Dr. Pieter Cullis Scientific Director & CEO Dr. Gilbert Walker Associate Scientific Director Dr. Diana Royce Executive Director

2. The Nanomedicines Innovation Network (NMIN) • NMIN’s vision:  • to establish and mobilize a national research and development network with participants drawn from academia, industry, and not-for-profit research enterprises, whose collective research, capacity building and commercialization efforts strengthen Canada’s position as a global leader in developing next generation nanomedicines, new Canadian companies and jobs OVERVIEW • NMIN’s mission:  • to develop novel therapeutics to cure high-burden human diseases and new diagnostics to detect disease more precisely • to commercialize these products to bring health and economic benefits to Canadians; and • to train the skilled workforce required by the growing nanomedicines industry

3. The Nanomedicines Innovation Network (NMIN) NMIN invests in proof-of-concept (PoC) and proof-of-principle (PoP) projects aimed at developing new therapeutics and diagnostics, the majority partnered with industry. Targets: 60 Principal Investigators 17 institutions across Canada 15 companies 8 not-for-profit research and granting institutions OVERVIEW

4. The Nanomedicines Innovation Network (NMIN) NMIN will focus its academic and commercial investments in three themes Nanomedicines that reduce toxicity and/or enhance efficacy of small molecule drugs OVERVIEW Nanomedicines that enable DNA, RNA-based drugs to be used as therapeutics Diagnostics based on nanotechnology that enable more precise detection and diagnosis of disease

5. The Nanomedicines Innovation Network (NMIN) • Core Facilities/Legacy Initiatives NanoCore – Translational Nanomedicines Formulation & Characterization Core Facility • Develops high-quality, state-of-the-art lipid nanoparticles encapsulating small molecule, peptide or nucleic acid drugs that enable proof-of-concept (POC) animal studies • Standardizes the physicochemical characterization in order to identify critical parameters OVERVIEW PharmaCore- Pharmacology/Toxicology & Scale-up Manufacturing Core Facility • Offers capabilities in: 1) Pre-Clinical Pharmacology; 2) cGLP Toxicology; 3) cGMP Parenteral Manufacturing and 4) Quality Management / Project Management

6. The Nanomedicines Innovation Network (NMIN) • First round of research investment The 20 projects in NMIN’s first round of research investment span 6 member institutions across 5 provinces Cores n=2 OVERVIEW Theme I Targeted Drug Delivery • n=8 Theme III Diagnostics • n=5 • The University of British Columbia (BC) • University of Alberta (AB) • University of Saskatchewan (SK) • University of Toronto & University Health Network (ON) • Polytechnique Montréal (QC) Theme II Gene Therapies • n=5 Distribution of research investments ($) by Theme

7. The Nanomedicines Innovation Network (NMIN) • Emerging Investment Strategy "Round 2" 2020 Rapid Response/Strategic Initiatives OVERVIEW Research Directed and Invited Theme 1: Drug Delivery Theme 2: Gene Therapy Theme 3: Diagnostics • Research • Commercialization • Knowledge Translation & Mobilization Discovery Innovation • ~$2.2M

8. The Nanomedicines Innovation Network (NMIN) NMIN NMIN will producecompletepre-clinical dossiers to support commercialization NMIN Industry partner 1 OVERVIEW Clinical validation Human samples proof of concept Proof of principle Application 1 Technology dossier • Able to detect diagnostic marker at clinical level in a way potentially more valuable than any current technology • Industry partner expresses interest in particular disease target or diagnostic technology • Analytical validity, clinical validity, clinical utility and economic utility • Design consistent with regulatory compliance • Intellectual property • Manufacturing, stability, market, etc. • Attractive to patients, providers and payers Proof of principle Application 2 Proof of principle Application 3 • Establish efficacy with human samples • Champions on both the clinical side and business side

9. The Nanomedicines Innovation Network (NMIN) NMIN will train the next generation of nanomedicine scientists & innovators OVERVIEW • NMIN trainees will benefit from: • multidisciplinary research opportunities arising from NMIN project investments • networking and collaborating with their peers and with world leaders in the field • training in the technology and business of nanomedicines, guided by the market needs of the R&D community • NMIN’s formal HQP Program, which will provide funding, mentorship and capacity-building opportunities beyond those typically available in traditional academic and laboratory settings • symposia, webinars, poster competitions, and other events and activities geared to HQP

10. The Nanomedicines Innovation Network (NMIN) NMIN will extend Canada’s global lead and bring goodhealth and wealth to Canadians! OVERVIEW

11. The Nanomedicines Innovation Network (NMIN) NMIN researchers have already developedsix of the ten approvednanomedicinesworldwide OVERVIEW

12. The Nanomedicines Innovation Network (NMIN) NMIN researchers haveestablished a world-leading nanomedicinescommercializationhub Dalriada Mesentech Genevant Glysantis NanoVista OVERVIEW Co-Motion Precision Genevant Integrated Established Nanomedicines Industry Comotion Acuitas Parmalat iNano Microdermics Evonik Mirexus Celator Suncor Cuprous Founded by NMIN Principals

13. The Nanomedicines Innovation Network (NMIN) NMIN will build on Canada’s leadership position by leveraging our exceptional academicinfrastructure OVERVIEW

14. The Nanomedicines Innovation Network (NMIN) Organizational structure NMIN Administrative Structure OVERVIEW

15. The Nanomedicines Innovation Network (NMIN) Board of Directors Board Chair OVERVIEW Helen Burt AVP, Research & Innovation, UBC Christine Charette • BOD observer on RMC • Managing Director, Scientia Advisors & Investments Chad Bayne Partner, Emerging & High Growth Companies, Osler Michael Coughtrie Professor & Dean, Faculty of Pharmaceutical Sciences, UBC • Don M. Enns • Head of Global Drug Delivery, Evonik Health Care Lesley Esford Director, Innovate BC Michael List Partner, GreenSky Capital Norma Sebestyen Ex-Director of Policy & Patient Access, Merck Rebecca Yu VP, Market Access & External Affairs, Takeda Canada

16. The Nanomedicines Innovation Network (NMIN) Research Management Committee – Part 1 Theme 1 Leaders Theme 2 Leaders Theme 3 Leaders OVERVIEW • GENETHERAPY • DIAGNOSTICS • TARGETED DRUG DELIVERY Marcel Bally PharmaCore Leader • Professor, Pathology & Laboratory Medicine, UBC Shana Kelley Professor, Pharmaceutical Sciences, University of Toronto Pieter Cullis • NanoCore Leader Professor, Biochemistry & Molecular Biology, UBC Shyh-Dar Li Associate Professor, Pharmaceutical Sciences, UBC Gilbert Walker Professor, Department of Chemistry, University of Toronto Christian Kastrup • NanoCore Co-Leader Associate Professor, Michael Smith Laboratories

17. The Nanomedicines Innovation Network (NMIN) Research Management Committee – Part 2 OVERVIEW • David O’Neill • External • FACIT • JP Heale • External • University of British Columbia • Norbert Maurer External • Evonik Transferra • ParimalNathwani • External • MaRS Innovation • Kaley Wilson • External Quark Venture • Nancy Dos Santos • PharmaCore Admin Lead Observer • Brigit Viens • NCE Secretariat Observer • Dominik Witzigmann • NanoCore Admin Lead Observer

18. The Nanomedicines Innovation Network (NMIN) • NMIN is looking for partnerships & collaborations to accelerate & extend Canada's current leadership in the field: • research: become an NMIN research partner—help create the ‘smart’ medicines of the future • commercialization: partner with NMIN innovators to bring cutting-edge new therapeutics & diagnostics from the lab to the clinic • training: support NMIN’s Mitacs-funded training opportunities to help cultivate the next generation of nanomedicine scientists & innovators • professional opportunities: hire an NMIN graduate—advertise your opportunities through our Network to reach the brightest emerging professionals in nanomedicine • outreach & networking: sponsor/attend NMIN conferences, scientific meetings or other events; share communications; invite NMIN speakers to your events • engagement: visit our website; sign up to receive our newsletters & press releases; join our LinkedIn group & follow us on Twitter OVERVIEW

19. The Nanomedicines Innovation Network (NMIN) Upcoming NMIN Events March 2020 Trainee Symposium Toronto, ON February 2021 NMIN Conference Toronto, ON June 2021 Liposome Research Days Vancouver, BC February 2022 Trainee Symposium Vancouver, BC December 2022 Scientific Meeting Toronto, ON February 2023 Trainee Symposium Toronto, ON February 2024 NMIN Conference Vancouver, BC OVERVIEW

20. Nanomedicines Innovation Network (NMIN) https://nanomedicines.ca info@nanomedicines.ca @NMIN_NCE Join NMIN’s LinkedIn Group: Nanomedicines Innovation Network https://bit.ly/2WgyEab